BVF Partners
BVF Partners is a venture capital firm that invests in early stage startup companies.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed BVF Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
BVF Partners is a venture capital firm that invests in early stage startup companies.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2014 | Blueprint Medicines | Series B | 25M |
| 5/2018 | Rain Therapeutics | Series A | 18.4M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 9/2022 | Nimbus Therapeutics | Venture Round | 0 |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 9/2013 | Evotec | Venture Round | 40M |
| 11/2001 | Phylogix Inc. | Series A | 3M |
| 3/2015 | Tobira Therapeutics | Convertible Note | 13M |
| 3/2004 | Phylogix Inc. | Series B | 12M |
| 3/2018 | ViewPoint Therapeutics | Series B | 0 |
| 8/2022 | Kymera Therapeutics | Post-IPO Equity | 150M |
| 8/2017 | Molecular Templates | Post-IPO Equity | 60M |
| 2/2018 | Merus | Post-IPO Equity | 55.8M |
| 12/2020 | Gritstone Bio | Post-IPO Equity | 125M |
| 2/2019 | Peloton Therapeutics | Series E | 0 |
| 11/2014 | Ziarco | Series B | 33M |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 7/2015 | AnaptysBio | Series D | 40M |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 12/2017 | Relay Therapeutics | Series B | 63M |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 5/2020 | Surface Oncology | Post-IPO Equity | 28.9M |
| 8/2018 | Olema Oncology | Series A | 6.1M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 11/2014 | GTx | Post-IPO Equity | 43.4M |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 9/2017 | Realm Therapeutics | Post-IPO Equity | 26M |
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 5/2013 | Cascadian Therapeutics | Post-IPO Equity | 10M |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 7/2017 | BiolineRx | Post-IPO Equity | 9.6M |
| 9/2010 | Addex Therapeutics | Post-IPO Equity | 19.9M |
| 8/2013 | Addex Therapeutics | Post-IPO Equity | 3.5M |
| 1/2003 | Biotica Technology | Series A | 5M |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 7/2021 | Nimbus Therapeutics | Private Equity Round | 105M |
| 6/2016 | Pieris Pharmaceuticals | Post-IPO Equity | 16.5M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 7/2020 | Olema Oncology | Series B | 54M |
| 4/2018 | Inventiva Pharma | Post-IPO Equity | 44.4M |
| 7/2021 | Nimbus Therapeutics | Venture Round | 0 |
| 4/2021 | Ventus Therapeutics | Series B | 0 |
| 3/2021 | Pyxis Oncology | Series B | 0 |
| 12/2020 | Gritstone Bio | Post-IPO Equity | 0 |
| 7/2020 | Olema Oncology | Series B | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 0 |
| 5/2020 | Surface Oncology | Post-IPO Equity | 0 |
| 3/2020 | Kymera Therapeutics | Series C | 0 |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 7/2019 | Revolution Medicines | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
